A Phase 3, Randomized, Observer-blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Comparison with a Licensed Quadrivalent Influenza Vaccine, in Adults 50 to 64 Years of Age - Phase 3 Immunogenicity Study of aQIV in Adults 50 to 64 Years of Age
100 Clinical Results associated with Seqirus UK Ltd.
0 Patents (Medical) associated with Seqirus UK Ltd.
100 Deals associated with Seqirus UK Ltd.
100 Translational Medicine associated with Seqirus UK Ltd.